Oral Oncolytics Will Require Health Care System to Adapt
Judging from the drug pipeline, the future of oncology is oral chemotherapy.
Related Articles
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.
Functional Precision Medicine Method Aids Treatment Decision-Making in R/R Pediatric Cancers
A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.
Parsaclisib Added to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores in Myelofibrosis
Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.
CAN-2409 Granted FDA Orphan Drug Designation in Pancreatic Cancer
CAN-2409 has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.
FDA Fast Track Designation Granted to LYT-200 in Recurrent/Metastatic HNSCC
The galectin-9–targeted monoclonal antibody LYT-200 received FDA fast track designation for recurrent/metastatic head and neck squamous cell cancer.
Improved Molecular Classification Drives Tailored Treatment Approaches in Endometrial Cancer
Abdulrahman Sinno, MD, discusses the paradigm shift from a histology-based to molecular-based understanding of endometrial cancer and its impact on treatment outcomes.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
The New Frontier With Integrative Oncology: Shooting for the Stars
Richard T. Lee, MD, and Edward S. Kim, MD, MBA, discuss the benefits of integrative oncology and exploring integrative approaches at the Cherng Family Center…
Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in Relapsed/Refractory NHL
The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.
Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence
Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.